CA2273847C - Diagnostic d'etat pathologique a l'aide de profils d'arn messager - Google Patents
Diagnostic d'etat pathologique a l'aide de profils d'arn messager Download PDFInfo
- Publication number
- CA2273847C CA2273847C CA2273847A CA2273847A CA2273847C CA 2273847 C CA2273847 C CA 2273847C CA 2273847 A CA2273847 A CA 2273847A CA 2273847 A CA2273847 A CA 2273847A CA 2273847 C CA2273847 C CA 2273847C
- Authority
- CA
- Canada
- Prior art keywords
- level
- psa
- pcr
- rna
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Cette invention, qui a trait à des méthodes diagnostiques permettant de déceler des états pathologiques chez l'homme, décrit également les sondes génétiques et les techniques afférentes utilisées pour déceler des états pathologiques et surveiller leur évolution. Elle concerne, plus particulièrement, des sondes et des techniques permettant d'évaluer la présence d'espèces d'ARN dont l'expression dans le sang périphérique de personnes souffrant desdits états pathologiques diffère de celle ayant lieu chez des individus en bonne santé. L'invention porte, en outre, sur un modèle de diagnostic à plusieurs variables s'appliquant au cancer de la cancer de la prostate chez des sujets dont le taux plasmatique total d'antigène prostatique spécifique (PSA) est modérément élevé (? 2,0 ng/ml). Les résultats de dosages sériques concernant le produit génique UC325 [Interleukine-8(IL-8)], le taux plasmatique total d'antigène prostatique spécifique (t-PSA) ainsi que les rapports relatifs à l'absence de PSA/PSA total (f/t PSA) ont été combinés pour renforcer la sensibilité du diagnostic du cancer de la prostate dans une population relevant de l'urologie diagnostiquée comme étant atteinte, soit d'un cancer de la prostate limité à l'organe proprement dit (stade clinique A et B), soit d'un cancer de la prostate non limité à l'organe (stade clinique C ou D) ou encore d'une hyperplasie prostatique bénigne (BPH). L'invention traite également des possibilités supplémentaires qu'offre la connaissance des taux sériques en produit génique UC325 de définir avec exactitude les stades d'évolution du cancer de la prostate, indépendamment des taux de PSA, qu'il s'agisse de t-PSA ou de f/t PSA.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3261996P | 1996-12-06 | 1996-12-06 | |
US60/032,619 | 1996-12-06 | ||
US3270196P | 1996-12-12 | 1996-12-12 | |
US60/032,701 | 1996-12-12 | ||
US4157697P | 1997-03-24 | 1997-03-24 | |
US60/041,576 | 1997-03-24 | ||
PCT/US1997/022105 WO1998024935A1 (fr) | 1996-12-06 | 1997-12-05 | DIAGNOSTIC D'ETAT PATHOLOGIQUE A L'AIDE DE PROFILS d'ARN MESSAGER |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2273847A1 CA2273847A1 (fr) | 1998-06-11 |
CA2273847C true CA2273847C (fr) | 2013-08-13 |
Family
ID=27364173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2273847A Expired - Fee Related CA2273847C (fr) | 1996-12-06 | 1997-12-05 | Diagnostic d'etat pathologique a l'aide de profils d'arn messager |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0960214A4 (fr) |
AU (1) | AU722819B2 (fr) |
CA (1) | CA2273847C (fr) |
WO (1) | WO1998024935A1 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO972006D0 (no) * | 1997-04-30 | 1997-04-30 | Forskningsparken I Aas As | Ny metode for diagnose av sykdommer |
US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
CA2359816C (fr) | 1999-01-06 | 2010-08-03 | Genenews Inc. | Technique de detection de transcrits geniques dans le sang et leur utilisation |
US20050123938A1 (en) * | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
US7473528B2 (en) | 1999-01-06 | 2009-01-06 | Genenews Inc. | Method for the detection of Chagas disease related gene transcripts in blood |
FI990382A0 (fi) * | 1999-02-23 | 1999-02-23 | Arctic Partners Oy Ab | Uusi diagnostinen menetelmä |
WO2001025473A1 (fr) * | 1999-06-28 | 2001-04-12 | Source Precision Medicine, Inc. | Systemes et techniques permettant de caracteriser un etat ou un agent biologique par expression genique calibree |
US6960439B2 (en) | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US6692916B2 (en) | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
IL148930A0 (en) * | 1999-10-13 | 2002-09-12 | Sequenom Inc | Methods for generating databases and databases for identifying polymorphic genetic markers |
AU2002241720A1 (en) * | 2000-11-08 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
US20030104393A1 (en) * | 2000-11-28 | 2003-06-05 | Sharp Frank R. | Blood assessment of injury |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
WO2003023056A2 (fr) | 2001-09-12 | 2003-03-20 | F. Hoffmann-La Roche Ag | Marqueurs specifiques a la sclerose en plaques |
WO2003040404A1 (fr) | 2001-11-09 | 2003-05-15 | Source Precision Medicine, Inc. | Identification, surveillance et traitement d'une maladie et definition d'un etat biologique a l'aide de profils d'expression genetique |
GB0200595D0 (en) * | 2002-01-11 | 2002-02-27 | Oxford Glycosciences Uk Ltd | Quantitation of differential expression |
CA2498418A1 (fr) * | 2002-09-10 | 2004-03-25 | Guennadi V. Glinskii | Methodes de segregation de genes et de classification d'echantillons biologiques |
BR0317612A (pt) * | 2002-12-19 | 2005-12-06 | Source Precision Medicine Inc | Identificação, monitoração e tratamento de doença infecciosa e caracterização de condições inflamatórias relacionadas com doença infecciosa empregando perfis de expressão de gene |
US9394565B2 (en) | 2003-09-05 | 2016-07-19 | Agena Bioscience, Inc. | Allele-specific sequence variation analysis |
CN101039951A (zh) * | 2003-11-03 | 2007-09-19 | 基因信息公司 | 肝癌生物标志物 |
EP2395098B1 (fr) | 2004-03-26 | 2015-07-15 | Agena Bioscience, Inc. | Division spécifique de base de produits d'amplification spécifique à la méthylation en combinaison avec une analyse de masse |
GB0510352D0 (en) * | 2005-05-20 | 2005-06-29 | Optomed As | Methods of prostate cancer diagnosis and prostrate tumour analysis |
EP1910571A2 (fr) | 2005-06-16 | 2008-04-16 | Source MDX | Profile d'expression génétique à des fins d'identification, de surveillance et de traitement de la sclérose en plaques |
CA2618657A1 (fr) * | 2005-08-11 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Procede d'evaluation d'un compose a l'aide d'une molecule sur le trajet rb comme indice et procede de diagnostic moleculaire |
WO2007038754A2 (fr) | 2005-09-27 | 2007-04-05 | Source Mdx | Profilage d'expression genique aux fins de surveillance de l'identification et de traitement de la polyarthrite rhumatoide |
US20100196889A1 (en) | 2006-11-13 | 2010-08-05 | Bankaitis-Davis Danute M | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer |
EP2405022A3 (fr) | 2008-07-08 | 2012-05-02 | Genomic Health, Inc. | Profilage de l'expression génétique pour prédire la capacité de survie de sujets atteints de cancer de la prostate |
US20120301887A1 (en) | 2009-01-06 | 2012-11-29 | Bankaitis-Davis Danute M | Gene Expression Profiling for the Identification, Monitoring, and Treatment of Prostate Cancer |
EP2407554A1 (fr) | 2010-07-14 | 2012-01-18 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Procédés et kits pour le diagnostic du cancer de la prostate |
EP2407555A1 (fr) | 2010-07-14 | 2012-01-18 | Fundació Institut de Recerca Hospital Universitari Vall d'Hebron, Fundació Privada | Procédés et kits pour le diagnostic du cancer de la prostate |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851764A (en) * | 1990-10-25 | 1998-12-22 | The Trustees Of Columbia University In The City Of New York | Human prostate tumor inducing gene-1 and uses thereof |
GB2250993B (en) * | 1990-11-21 | 1995-02-15 | Inst Nat Sante Rech Med | Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer |
AU662906B2 (en) * | 1991-06-26 | 1995-09-21 | F. Hoffmann-La Roche Ag | Methods for detection of carcinoma metastases by nucleic acid amplification |
EP0667920B1 (fr) * | 1992-10-29 | 2003-01-15 | Thomas Jefferson University | Procedes de detection de micrometastase du cancer de la prostate |
US5459037A (en) * | 1993-11-12 | 1995-10-17 | The Scripps Research Institute | Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations |
US5677125A (en) * | 1994-01-14 | 1997-10-14 | Vanderbilt University | Method of detection and diagnosis of pre-invasive cancer |
US5539096A (en) * | 1994-09-08 | 1996-07-23 | Universite De Montreal | Genes differentially expressed in metastatic and non-metastatic rat rhabdomyosarcoma cell lines |
GB9423912D0 (en) * | 1994-11-26 | 1995-01-11 | Imp Cancer Res Tech | Detecting tumours |
AU4182697A (en) * | 1996-09-06 | 1998-03-26 | Trustees Of Columbia University In The City Of New York, The | Use of prostate tumor inducing gene for detection of cancer cells |
US5932442A (en) * | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
-
1997
- 1997-12-05 AU AU55151/98A patent/AU722819B2/en not_active Ceased
- 1997-12-05 WO PCT/US1997/022105 patent/WO1998024935A1/fr not_active Application Discontinuation
- 1997-12-05 EP EP97951529A patent/EP0960214A4/fr not_active Ceased
- 1997-12-05 CA CA2273847A patent/CA2273847C/fr not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU5515198A (en) | 1998-06-29 |
AU722819B2 (en) | 2000-08-10 |
WO1998024935A1 (fr) | 1998-06-11 |
EP0960214A4 (fr) | 2004-08-04 |
CA2273847A1 (fr) | 1998-06-11 |
EP0960214A1 (fr) | 1999-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2273847C (fr) | Diagnostic d'etat pathologique a l'aide de profils d'arn messager | |
US6190857B1 (en) | Diagnosis of disease state using MRNA profiles in peripheral leukocytes | |
US6090559A (en) | Biomarkers for the detection of prostate cancer | |
CA2744096C (fr) | Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate | |
US6218529B1 (en) | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer | |
TWI503416B (zh) | 檢測膀胱癌之尿液標記物 | |
US8551700B2 (en) | Diagnostic and prognostic tests | |
US7807785B2 (en) | Androgen regulated prostate specific nucleic acids | |
JP2004503261A (ja) | 分子マーカー | |
CA2328377A1 (fr) | Nouveau procede de diagnostic, de surveillance et de stadification du cancer de la prostate | |
US7332270B1 (en) | Diagnosis of disease state using mRNA profiles in peripheral leukocytes | |
AU2021202735A1 (en) | Urine markers for detection of bladder cancer | |
Karavitaki et al. | Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy | |
AU2011236061B2 (en) | Urine markers for detection of bladder cancer | |
KR20200104106A (ko) | 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커 | |
AU712403B2 (en) | Biomarkers and targets for diagnosis, prognosis and management of prostate disease | |
WO2002081656A2 (fr) | Potentiel diagnostique ameliore de cellules exprimant l'antigene specifique de la prostate | |
KR20210040921A (ko) | 신장암 환자의 치료 전략 결정 및 예후 진단용 재발 특이적 마커 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20161205 |